Genomics company DxTerity Diagnostics reported on Monday the receipt of US FDA Emergency Use Authorization (EUA 202120) for its updated SARS-CoV-2 RT-PCR test, SafeWorkDx, for the home as well as in the workplace to help prevent the spread of COVID-19.
The company revealed the SARS-CoV-2 test has been authorized for testing specimens collected from individuals suspected of COVID-19 by their healthcare provider (HCP) and from any individual, including from individuals without symptoms or other reasons to suspect COVID-19. The simple and streamlined testing process provides sample collection materials and a 48-hour stabilization kit for transport of samples.
According to the company, the kit is equipped with a SDNA-1000 Saliva Collection Device and provides secure barcoded tracking of specimen to ensure the samples can be de-identified and accurately traced for security and privacy purposes.
In conjunction, the company said it will be unrolling additional ordering capabilities in the coming weeks to meet the need for increased testing during the holiday season, providing peace of mind as people return to work.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT